S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
NCT00343668
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
44
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
S-1, irinotecan
Sponsor
Korean Cancer Study Group